The results of a late-stage drug trial released Thursday are raising hopes that type 1 diabetes patients with chronic kidney ...

The results of two large-scale studies demonstrate that sodium-glucose co-transporter 2 (SGLT2) inhibitors significantly ...

Other risk factors for kidney disease include chronic infections, autoimmune disorders, and certain genetic variants. The new ...

The drug finerenone has a positive effect on patients with type 1 diabetes and chronic kidney disease. The drug reduces the ...

The combination of Merck's Welireg and Eisai's Lenvima has not yet shown statistical significance in extending overall ...

George Tidmarsh has lost his job as director of the U.S. FDA's Center for Drug Evaluation and Research amid accusations that he leveled false statements against a Canadian drugmaker and disparaged one ...

Patients on hemodialysis, either in a center or at home, who used a specialized kidney pharmacy program had lower mortality ...

Merck and Eisai's experimental combination treatment helped extend the time certain patients with advanced kidney cell cancer ...

The deal involves Eli Lilly, which makes Zepbound and Mounjaro, and Novo Nordisk, the maker of Ozempic and Wegovy. The drugs, ...

aProximate TM PTCs maintain high expression of key transporters involved in drug handling, including megalin and cubilin, making them ideal for studying drug transporters and drug interactions with ...

In 2002, the Kidney Disease Outcomes Quality Initiative developed guidelines that classify CKD into five stages. It is challenging to estimate the total CKD population, as early-to-moderate CKD is ...

Chronic kidney disease is a gradual, irreversible loss of kidney function caused by diabetes, hypertension, or ageing. It ...